The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

Acceptance summary:

In agreement with the accumulating evidence that the D614G mutation in the SARS-CoV-2 Spike protein is associated with a selective advantage for viral spread, the present study shows that this mutation increases transduction by Spike containing lentiviral particles as well as the infectiousness of genuine SARS-CoV-2 in human lung epithelial cells. The authors further report that the D614G changes hardly affect ACE2 receptor binding, but do affect the sensitivity of the Spike protein to proteolytic cleavage, which might help to explain effects on viral infectivity.

Decision letter after peer review:

Thank you for submitting your article "The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types" for consideration by eLife. Your article has been reviewed by three peer reviewers, including Frank Kirchhoff as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Sara Sawyer as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is "in revision at eLife". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

Daniloski and colleagues examined the functional consequences of a D614G mutation in the SARS-CoV-2 Spike protein that seems to be associated with a selective advantage for viral spread in the human population. They confirm that viruses harboring mutation D614G became dominant in the pandemic and further show that this mutation increases transduction by Spike containing lentiviral particles in several cell lines including human lung epithelial cells. The authors further report that the D614G change hardly affects ACE2 receptor binding but renders the Spike protein less sensitive to proteolytic cleavage. Finally, they conclude that their results are important for the efficacy of Spike-based vaccines.

Determining the impact of D614G variants on the course of the pandemic and clarifying how D614G modulates virus-host cell interactions is important. Recently, several studies have been published on this subject that show, among other findings, that D614G increases entry and viral fitness. Moreover, mechanistic explanations for increased entry have been provided, including G614 spike being more frequently in an ACE2 binding-competent conformation (PMID: 33106671, PMID: 32730807, PMID: 32991842, PMID: 33184236, PMID: 33243994). In the light of these studies, the novelty of the findings reported in the present study is limited but the results are still of significant interest. For most part the data seem solid. As outlined below, however, some overstatements should be avoided and conclusions on the mechanism seem rather preliminary based on the results presented. Furthermore, limitations of the present study (e.g. that all but one cell line overexpress ACE2) should be clearly stated and discrepancies to other studies investigating the effect on the D614G change need to be discussed.

Essential revisions:

1) "This result has important implications for the efficacy of Spike-based vaccines currently under development in protecting against this recent and highly-prevalent SARS-CoV-2 isolate." The authors did not analyze whether the D614G mutation affects vaccine efficiency and recent data suggest that this might not be the case. Thus, this statement should be removed from the Abstract.

2) Enhancing effects varied from about 2-to 8-fold and the strongest effects were obtained in cells overexpressing ACE2. The authors should not only mention the maximum effect but provide the range in the Abstract. More importantly, transduction data can hardly be evaluated in the absence of data on S protein incorporation into particles. Increased entry driven by D614G spike might simply reflect increased particle incorporation in the pseudotyping system used by the authors. This should be examined. In addition, the significance of the results would be strengthened by analyses of D614G spike-mediated transduction of human lung cell lines or (better) primary lung cells that endogenously express ACE2 and TMPRSS2. Otherwise the caveat that the strongest effects were observed under conditions of ACE2 overexpression should already be clearly stated in the Abstract.

3) Cleavage was only analyzed in HEK293T cells and only total spike present in cells is shown. However, the cleavage status of spike present in particles (and not in cells) impacts spike protein-mediated entry. This could easily be tested; however, Ozono and colleagues reported that the effect of D614G is independent of virion incorporation of the S protein. Unlike the present study, Yurkovetskiy and colleagues reported that D614G affinity for ACE2 is reduced due to a faster dissociation rate and He et al. reported that the G614 S protein was cleaved more efficiently by serine protease elastase-2. These discrepancies should be discussed.

4) The observation that D614 increases SARS-CoV-2 infection of human cells grown in culture is meanwhile well established. All relevant literature, e.g. https://www.cell.com/cell/fulltext/S0092-8674(20)30877-1; https://www.nature.com/articles/s41586-020-2895-3; https://www.nature.com/articles/s41392-020-00392-4 should be cited and priority claims avoided. The authors should discuss the different models presented in the literature regarding exactly how D614G increases infectivity, and they should compare and contrast their results with these other hypotheses. There are several other locations where text in this manuscript needs to be updated. For instance, there are many more than 10 vaccines in clinical trials at the moment (Results).